Acalabrutinib in Combination With ACP-319, for Treatment of Chronic Lymphocytic Leukemia
Status:
Active, not recruiting
Trial end date:
2025-12-31
Target enrollment:
Participant gender:
Summary
This study is evaluating the safety and efficacy of the combined use of acalabrutinib and
ACP-319, for the treatment of chronic lymphocytic leukemia (CLL)